Halozyme Therapeutics (0J2O.L) Stock Price

$68 0.4%

Sign up
to add to portfolio

AI Score

Hold

  • Alternative

    7

  • Fundamental

    8

  • Technical

    6

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Halozyme Therapeutics, AI stock picks, stock alerts and much more.

Sign up

0J2O.L AI Stock Analysis

AI stock analysis for 0J2O.L is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Halozyme Therapeutics (0J2O.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

Halozyme Therapeutics (0J2O.L) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Halozyme Therapeutics (0J2O.L), currently trading at $68, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About 0J2O.L

LSE

  • Halozyme Therapeutics, Inc.

  • Symbol

    0J2O.L

  • Market

    LSE

  • Industry

    Medical - Pharmaceuticals

  • Market Cap

    8B

Similar Stocks

0QZU.L Vertex Pharmaceuticals Incorporated
0QZU.L		 $390.4
1.1%
7
0K6R.L Neurocrine Biosciences
0K6R.L		 $133.6
0.9%
7
0IGA.L Emergent BioSolutions Inc.
0IGA.L		 $8.88
1%
4
0H7R.L Abeona Therapeutics Inc.
0H7R.L		 $6.93
3.9%
5
0LSZ.L Walgreens Boots Alliance
0LSZ.L		 $11.99
0.6%
5

News

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years

Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years
April 22, 2025. Biztoc.com
Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $58.00 at JPMorgan Chase & Co.

Halozyme Therapeutics (NASDAQ:HALO) Price Target Raised to $58.00 at JPMorgan Chase & Co.
April 21, 2025. ETF Daily News
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by CIBC Private Wealth Group LLC

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by CIBC Private Wealth Group LLC
April 8, 2025. ETF Daily News
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by California Public Employees Retirement System

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by California Public Employees Retirement System
April 7, 2025. ETF Daily News

0J2O.L Alternative Data

Web Traffic

Halozyme Therapeutics receives an estimated 8757 monthly visitors to halozyme.com.

  • Web Traffic

    8757

  • Change from Previous Month

    32.9%

  • 3 Month Change

    7.9%

  • YoY Change

    7.9%

Twitter Followers

Halozyme Therapeutics has 632 Twitter Followers on its main Twitter (also known as X) account, which is up by 1.3% over the last month.

  • Twitter Followers

    632

  • Daily Change

    0%

  • 1 Month Change

    1.3%

  • 3 Month Change

    3.1%

  • YoY Change

    3.1%

Youtube Subscribers

Halozyme Therapeutics has 78 subscribers on its main Youtube channel, up by 1.3% over the last month.

  • Youtube Subscribers

    78

  • Daily Change

    0%

  • 1 Month Change

    1.3%

  • 3 Month Change

    1.3%

Job Postings

Halozyme Therapeutics has an estimated 10 open job postings, which is down -23.1% over the last month.

  • Job Postings

    10

  • Daily Change

    16.7%

  • 1 Month Change

    23.1%

  • 3 Month Change

    11.1%

  • YoY Change

    11.1%

Reddit Mentions

Halozyme Therapeutics has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

LinkedIn Followers

20,962 are following Halozyme Therapeutics on LinkedIn, up by 0.8% over the last month.

  • LinkedIn Followers

    20962

  • Daily Change

    0.8%

  • 1 Month Change

    0.8%

  • 3 Month Change

    2.6%

  • YoY Change

    2.6%

LinkedIn Employees

According to LinkedIn, Halozyme Therapeutics has 465 employees, up by 1.1% over the last month.

  • LinkedIn Employees

    465

  • Daily Change

    1.1%

  • 1 Month Change

    1.1%

  • 3 Month Change

    0.9%

  • YoY Change

    0.9%

Business Outlook

According to employee reviews, the business outlook among employees at Halozyme Therapeutics is 73 out of 100 (bullish).

  • Business Outlook

    73

  • Change from Previous Month

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

News Mentions

Halozyme Therapeutics was mentioned 0 times in the news yesterday.

  • News Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

0J2O.L Financials

0J2O.L Key Metrics

  • Total Revenue

    $264.9M

  • Net Income

    $118.1M

  • Earnings per Share

    $0.96

  • Free cash flow

    $153.3M

  • EBITDA

    $168.8M

  • EBITDA Ratio

    0.637323

  • Total Assets

    $2.2B

0J2O.L 2-year Revenue & Income
0J2O.L 2-year Free Cash Flow

0J2O.L Technicals

0J2O.L SMA
0J2O.L RSI

FAQ

What's the current price of Halozyme Therapeutics (0J2O.L) Stock?
The price of an Halozyme Therapeutics (0J2O.L) share is $68.

What's the market cap of Halozyme Therapeutics?
The current market cap of Halozyme Therapeutics is 8B.

Should I buy or sell 0J2O.L?
Multiple alternative data signals suggest that Halozyme Therapeutics stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.

Is Halozyme Therapeutics a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in Halozyme Therapeutics stock. The bullish indicators suggest that Halozyme Therapeutics' growth prospects and market position may lead to a positive performance in the foreseeable future.

Is now a good time to buy Halozyme Therapeutics (0J2O.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying Halozyme Therapeutics stock, given the bullish outlook.

What are some stocks similar to Halozyme Therapeutics (0J2O.L) that investors often compare it to?
Halozyme Therapeutics (0J2O.L) is often compared to similar stocks such as Vertex Pharmaceuticals Incorporated, Neurocrine Biosciences, Emergent BioSolutions Inc., Abeona Therapeutics Inc. and Walgreens Boots Alliance.

What is the forecast for Halozyme Therapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Halozyme Therapeutics' stock price to be around $73.01 in 2026. Starting from the current price of $68, this represents a 7.4% change in price, indicating a bullish outlook for the stock.

How to buy Halozyme Therapeutics (0J2O.L) Stock?
Halozyme Therapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Halozyme Therapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.